Drug Combo Proves Powerful Against Lung Cancer Hilton NY

A two-drug combination treatment in Hilton proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

JOHN BENNETT, MD
(585) 275-4915
601 Elmwood Avenue
Rochester, NY
JULIA SMITH, MD
(585) 922-4247
1425 Portland Avenue
Rochester, NY
Cynthia Angel, MD
716-442-8020
125 Lattimore Rd Ste 258
Rochester, NY
Lauren Beth Bruckner, MD
585-275-2981
601 Elmwood Ter
Rochester, NY
Gordon Leigh Phillips II, MD
585-273-4399
601 Elmwood Ave # 704
Rochester, NY
MICHAEL BECKER, MD
(585) 275-0784
601 Elmwood Avenue
Rochester, NY
SCOTT BARRETT, MD
(585) 475-8700
211 White Spruce Boulevard
Rochester, NY
ELIAS NICOLAS, MD
(585) 442-2626
2851 Monroe Avenue
Rochester, NY
Zachary B Kramer, MD
585-922-4020
1425 Portland Ave
Rochester, NY
Edward Jos Walsh, MD
1425 Portland Ave
Rochester, NY
Data Provided by:
  

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Exercise for Breast Cancer Survival Hilton NY
Breast cancer is a physically and emotionally traumatizing disease. A study underrtaken at the Harvard School of Public Health examined four observational studies to determine whether physical activity could improve quality of life after a breast cancer diagnosis and on increased breast cancer survival.
- Hormone Therapy for Lung Cancer Hilton NY
- Exercise for Prostate Cancer Hilton NY
- Genetic Clues for Skin Cancer Therapies Hilton NY
- Side Effect Of Chemotherapy Drugs Hilton NY
- Delayed Prostate Cancer Therapy Hilton NY
- Fungal Infection Treatments Hilton NY
- Hormone Therapy for Breast Cancer Hilton NY
- Risks for Childhood Cancer Survivors Hilton NY